Recently, the results of ASTRUM-007 trial, which assessed the efficacy and safety of serplulimab plus cisplatin plus 5-fluorouracil (serplulimab plus CF) versus cisplatin plus 5-fluorouracil (CF) alone as a first-line treatment in patients with advanced or metastatic ESCC with PD-L1 combined positive score (CPS) ≥ 110. Here, CD274 is linked to esophageal squamous cell carcinoma.